Genetics of caffeine consumption and responses to caffeine.

Coffee, caffeine, and risk of depression among women. Arch Intern Med (2011) 3.05

Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet (2011) 1.77

Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov (2013) 1.74

Do initial responses to drugs predict future use or abuse? Neurosci Biobehav Rev (2012) 1.26

Genetic Determinants of the Gut Microbiome in UK Twins. Cell Host Microbe (2016) 1.08

Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Mol Psychiatry (2014) 1.01

A review of the receptor-binding properties of p-synephrine as related to its pharmacological effects. Oxid Med Cell Longev (2011) 0.98

A review of the human clinical studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p-synephrine. Int J Med Sci (2012) 0.98

Effects of p-synephrine alone and in combination with selected bioflavonoids on resting metabolism, blood pressure, heart rate and self-reported mood changes. Int J Med Sci (2011) 0.90

Caffeine Use Disorder: A Comprehensive Review and Research Agenda. J Caffeine Res (2013) 0.89

Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics (2013) 0.88

Reduced neurobehavioral impairment from sleep deprivation in older adults: contribution of adenosinergic mechanisms. Front Neurol (2012) 0.86

Genetic factors modulating the response to stimulant drugs in humans. Curr Top Behav Neurosci (2012) 0.84

Health benefits of methylxanthines in cacao and chocolate. Nutrients (2013) 0.82

New biomarkers of coffee consumption identified by the non-targeted metabolomic profiling of cohort study subjects. PLoS One (2014) 0.81

Cumulative neurobehavioral and physiological effects of chronic caffeine intake: individual differences and implications for the use of caffeinated energy products. Nutr Rev (2014) 0.81

Affect-modulated startle: interactive influence of catechol-O-methyltransferase Val158Met genotype and childhood trauma. PLoS One (2012) 0.79

ADORA2A Gene variation, caffeine, and emotional processing: a multi-level interaction on startle reflex. Neuropsychopharmacology (2011) 0.79

Caffeine induction of sulfotransferases in rat liver and intestine. J Appl Toxicol (2011) 0.78

Caffeine choice prospectively predicts positive subjective effects of caffeine and d-amphetamine. Drug Alcohol Depend (2011) 0.77

Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: mechanisms and mediators. Br J Pharmacol (2012) 0.77

More on ADORA. Psychopharmacology (Berl) (2010) 0.77

Modification of caffeine effects on the affect-modulated startle by neuropeptide S receptor gene variation. Psychopharmacology (Berl) (2012) 0.76

Common psychiatric disorders and caffeine use, tolerance, and withdrawal: an examination of shared genetic and environmental effects. Twin Res Hum Genet (2012) 0.76

Genome-wide association analysis of tolerance to methylmercury toxicity in Drosophila implicates myogenic and neuromuscular developmental pathways. PLoS One (2014) 0.75

Practical Issues in Evidence-Based Use of Performance Supplements: Supplement Interactions, Repeated Use and Individual Responses. Sports Med (2017) 0.75

Caffeine consumption during pregnancy and ADHD at the age of 11 years: a birth cohort study. BMJ Open (2016) 0.75

Anxiety sensitivity and expectation of arousal differentially affect the respiratory response to caffeine. Psychopharmacology (Berl) (2014) 0.75

The Safety of Ingested Caffeine: A Comprehensive Review. Front Psychiatry (2017) 0.75

Cardiac damage in athlete's heart: When the "supernormal" heart fails! World J Cardiol (2017) 0.75

Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev (1999) 6.26

The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci (2001) 4.17

Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med (2007) 3.73

Genetic and environmental influences on alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood. Arch Gen Psychiatry (2008) 3.57

Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol (2009) 3.22

Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol (2001) 3.09

Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA (2000) 2.89

Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence. Arch Gen Psychiatry (2007) 2.79

Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc (2005) 2.79

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol (1999) 2.57

Caffeine metabolism, genetics, and perinatal outcomes: a review of exposure assessment considerations during pregnancy. Ann Epidemiol (2005) 2.54

Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA (2006) 2.40

Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci (2005) 2.34

Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci (2006) 2.29

Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol (1983) 2.04

Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest (1981) 2.03

Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol (2002) 1.97

Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res (1992) 1.96

Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci (2001) 1.90

An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem (2007) 1.87

Blood pressure response to caffeine shows incomplete tolerance after short-term regular consumption. Hypertension (2004) 1.83

Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci (2004) 1.81

Symptoms of anxiety and symptoms of depression. Same genes, different environments? Arch Gen Psychiatry (1987) 1.75

Effects of caffeine, sleep loss, and stress on cognitive performance and mood during U.S. Navy SEAL training. Sea-Air-Land. Psychopharmacology (Berl) (2002) 1.73

Clinical pharmacology of caffeine. Annu Rev Med (1990) 1.73

Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology (2003) 1.65

Consumption of coffee is associated with reduced risk of death attributed to inflammatory and cardiovascular diseases in the Iowa Women's Health Study. Am J Clin Nutr (2006) 1.64

Does coffee drinking increase the risk of coronary heart disease? Results from a meta-analysis. Br Heart J (1994) 1.60

A multivariate genetic analysis of the use of tobacco, alcohol, and caffeine in a population based sample of male and female twins. Drug Alcohol Depend (1999) 1.57

Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther (1991) 1.55

Spectral characteristics of sleep EEG in chronic insomnia. Eur J Neurosci (1998) 1.52

Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology (2003) 1.48

Acute and long-term cardiovascular effects of coffee: implications for coronary heart disease. Pharmacol Ther (2008) 1.46

Does caffeine intake protect from Alzheimer's disease? Eur J Neurol (2002) 1.46

Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. Eur Psychiatry (2000) 1.45

Heavy consumption of cigarettes, alcohol and coffee in male twins. J Stud Alcohol (1997) 1.44

Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl) (2005) 1.44

Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens (2005) 1.43

A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther (2007) 1.40

Coffee, caffeine and blood pressure: a critical review. Eur J Clin Nutr (1999) 1.36

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol (2008) 1.34

Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr (2007) 1.32

Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology (2008) 1.31

Dietary patterns and heritability of food choice in a UK female twin cohort. Twin Res Hum Genet (2007) 1.29

The effects of low doses of caffeine on human performance and mood. Psychopharmacology (Berl) (1987) 1.27

Twin studies of psychiatric illness. Current status and future directions. Arch Gen Psychiatry (1993) 1.25

Heritability and genetic covariation of sensitivity to PROP, SOA, quinine HCl, and caffeine. Chem Senses (2006) 1.24

Caffeine and nicotine: a review of their joint use and possible interactive effects in tobacco withdrawal. Addict Behav (1994) 1.24

Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics (2008) 1.22

Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br J Clin Pharmacol (1986) 1.20

The pharmacology of caffeine. Prog Drug Res (1987) 1.20

Coffee consumption and risk of coronary heart disease: a meta-analysis. Nutr Metab Cardiovasc Dis (2006) 1.20

Caffeine--an atypical drug of dependence. Drug Alcohol Depend (1998) 1.19

Effect of coffee on endothelial function in healthy subjects: the role of caffeine. Clin Sci (Lond) (2005) 1.18

The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics (2002) 1.14

The consumption of tobacco, alcohol, and coffee in Caucasian male twins: a multivariate genetic analysis. J Subst Abuse (1996) 1.14

Coffee use prior to myocardial infarction restudied: heavier intake may increase the risk. Am J Epidemiol (1990) 1.14

Caffeine and the dopaminergic system. Behav Pharmacol (2005) 1.13

Caffeine tolerance and choice in humans. Psychopharmacology (Berl) (1992) 1.09

Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport (1998) 1.08

Caffeine intake, tolerance, and withdrawal in women: a population-based twin study. Am J Psychiatry (1999) 1.08

Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology (2004) 1.08

Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry (1985) 1.07

Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. Mol Psychiatry (1998) 1.07

Heritability of substance use in the NAS-NRC Twin Registry. Acta Genet Med Gemellol (Roma) (1990) 1.07

The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacol Biochem Behav (1997) 1.06

Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther (1994) 1.06

The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension (1999) 1.05

Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants. Am J Med Genet B Neuropsychiatr Genet (2005) 1.04

A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiol Dis (2009) 1.04

Chronic caffeine consumption increases the number of brain adenosine receptors. Life Sci (1983) 1.02

Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain. Cell Mol Neurobiol (1993) 1.02

Low-dose caffeine discrimination and self-reported mood effects in normal volunteers. J Exp Anal Behav (1992) 1.02

The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol (1996) 1.01

Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther (1998) 0.99

Reinforcing effects of caffeine in humans. J Pharmacol Exp Ther (1988) 0.99

Adenosine A2a receptor-mediated modulation of striatal [3H]GABA and [3H]acetylcholine release. J Neurochem (1994) 0.99

The genetics of tea and coffee drinking and preference for source of caffeine in a large community sample of Australian twins. Addiction (2005) 0.98

The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition. Br J Clin Pharmacol (1983) 0.95

Hemodynamic mechanisms underlying the incomplete tolerance to caffeine's pressor effects. Am J Cardiol (2005) 0.95

Hypertension risk status and effect of caffeine on blood pressure. Hypertension (2000) 0.94

Functional uncoupling of adenosine A(2A) receptors and reduced responseto caffeine in mice lacking dopamine D2 receptors. J Neurosci (2000) 0.94

Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience (1991) 0.94

Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther (2003) 0.92

Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br J Pharmacol (2002) 0.91

Catechol-o-methyltransferase gene polymorphism modifies the effect of coffee intake on incidence of acute coronary events. PLoS One (2006) 0.91

The cardiovascular effects of regular and decaffeinated coffee. Br J Clin Pharmacol (1985) 0.89

Genetics of coffee consumption and its stability. Addiction (2008) 0.89

Role of adenosine A1 receptors in the modulation of dopamine D1 and adenosine A2A receptor signaling in the neostriatum. Neuroscience (2006) 0.89

A genetic analysis of coffee consumption in a sample of Dutch twins. Twin Res Hum Genet (2009) 0.89

Coffee, caffeine-related genes, and Parkinson's disease: a case-control study. Mov Disord (2008) 0.89

Caffeine effects on cardiovascular and neuroendocrine responses to acute psychosocial stress and their relationship to level of habitual caffeine consumption. Psychosom Med (1990) 0.88

"No thanks, it keeps me awake": the genetics of coffee-attributed sleep disturbance. Sleep (2007) 0.88

Caffeine enhances acetylcholine release in the hippocampus in vivo by a selective interaction with adenosine A1 receptors. J Pharmacol Exp Ther (1995) 0.86

Anxiety and caffeine consumption in people with anxiety disorders. Psychiatry Res (1985) 0.86

Panic disorder and social anxiety disorder subtypes in a caffeine challenge test. Psychiatry Res (2009) 0.84

Differences in pharmacokinetic and electroencephalographic responses to caffeine in sleep-sensitive and non-sensitive subjects. C R Biol (2006) 0.84

Effects of chronic caffeine on brain adenosine receptors: regional and ontogenetic studies. Life Sci (1984) 0.84

Association study of A2a adenosine receptor genetic polymorphism in panic disorder. Neurosci Lett (2004) 0.83

Exploring an interaction of adenosine A2A receptor variability with coffee and tea intake in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet (2006) 0.83

The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37

The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet (2003) 3.96

High-resolution genetic mapping using the Mouse Diversity outbred population. Genetics (2012) 3.28

Preference for immediate over delayed rewards is associated with magnitude of ventral striatal activity. J Neurosci (2006) 3.10

Rewarding, stimulant, and sedative alcohol responses and relationship to future binge drinking. Arch Gen Psychiatry (2011) 2.71

A genomewide screen of 345 families for autism-susceptibility loci. Am J Hum Genet (2003) 2.51

Biphasic alcohol response differs in heavy versus light drinkers. Alcohol Clin Exp Res (2002) 2.39

Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology (2003) 2.37

Genome-wide association studies and the problem of relatedness among advanced intercross lines and other highly recombinant populations. Genetics (2010) 2.06

Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav (2002) 1.94

Behavioral and biological indicators of impulsivity in the development of alcohol use, problems, and disorders. Alcohol Clin Exp Res (2010) 1.87

Acute-alcohol effects on the Experiential Discounting Task (EDT) and a question-based measure of delay discounting. Pharmacol Biochem Behav (2006) 1.83

Genetic analysis in the Collaborative Cross breeding population. Genome Res (2011) 1.74

Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest (2009) 1.67

Behavioral differences among C57BL/6 substrains: implications for transgenic and knockout studies. J Neurogenet (2008) 1.66

Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology (2003) 1.65

Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci (2008) 1.55

Social neuroscience and its potential contribution to psychiatry. World Psychiatry (2014) 1.48

Menstrual cycle phase and responses to drugs of abuse in humans. Drug Alcohol Depend (2006) 1.47

QTLRel: an R package for genome-wide association studies in which relatedness is a concern. BMC Genet (2011) 1.46

Effects of sleep deprivation on impulsive behaviors in men and women. Physiol Behav (2007) 1.44

Incubation of cue-induced cigarette craving during abstinence in human smokers. Biol Psychiatry (2011) 1.44

A common and unstable copy number variant is associated with differences in Glo1 expression and anxiety-like behavior. PLoS One (2009) 1.44

Amping up effort: effects of d-amphetamine on human effort-based decision-making. J Neurosci (2011) 1.43

Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry (2010) 1.39

Bupropion improves attention but does not affect impulsive behavior in healthy young adults. Exp Clin Psychopharmacol (2008) 1.36

Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology (2005) 1.34

Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J Clin Psychopharmacol (2008) 1.34

Test-retest characteristics of the Balloon Analogue Risk Task (BART). Exp Clin Psychopharmacol (2008) 1.32

Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res (2006) 1.31

Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology (2008) 1.31

Association between the casein kinase 1 epsilon gene region and subjective response to D-amphetamine. Neuropsychopharmacology (2006) 1.30

Effect of tryptophan depletion on impulsive behavior in men with or without a family history of alcoholism. Behav Brain Res (2002) 1.28

GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend (2002) 1.27

Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl) (2009) 1.27

Genetic variation and population substructure in outbred CD-1 mice: implications for genome-wide association studies. PLoS One (2009) 1.27

Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users. Psychopharmacology (Berl) (2006) 1.24

Differential effects of nicotine on alcohol consumption in men and women. Psychopharmacology (Berl) (2006) 1.24

The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl) (2012) 1.22

Significance thresholds for quantitative trait locus mapping under selective genotyping. Genetics (2007) 1.22

Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants. Exp Clin Psychopharmacol (2009) 1.21

Effects of morphine and naltrexone on impulsive decision making in rats. Psychopharmacology (Berl) (2004) 1.21

Balanced placebo design with marijuana: pharmacological and expectancy effects on impulsivity and risk taking. Psychopharmacology (Berl) (2012) 1.21

Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. Alcohol Clin Exp Res (2003) 1.20

Hormonal, cardiovascular, and subjective responses to acute stress in smokers. Psychopharmacology (Berl) (2008) 1.19

Personality and the subjective effects of acute amphetamine in healthy volunteers. Neuropsychopharmacology (2006) 1.19

Amphetamine-induced place preference in humans. Biol Psychiatry (2008) 1.17

Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13). PLoS One (2012) 1.14

Variation in the form of Pavlovian conditioned approach behavior among outbred male Sprague-Dawley rats from different vendors and colonies: sign-tracking vs. goal-tracking. PLoS One (2013) 1.12

Hardy-Weinberg disequilibrium identified genotyping error of the serotonin transporter (SLC6A4) promoter polymorphism. Psychiatr Genet (2006) 1.12

Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine. Psychiatr Genet (2010) 1.11

Nucleus accumbens lesions decrease sensitivity to rapid changes in the delay to reinforcement. Behav Brain Res (2006) 1.10

A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine. Psychopharmacology (Berl) (2008) 1.10

Candidate gene studies of a promising intermediate phenotype: failure to replicate. Neuropsychopharmacology (2012) 1.08

The combined effects of alcohol, caffeine, and expectancies on subjective experience, impulsivity, and risk-taking. Exp Clin Psychopharmacol (2013) 1.08

Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair. Proc Natl Acad Sci U S A (2014) 1.07

Effects of acute psychosocial stress on cigarette craving and smoking. Nicotine Tob Res (2010) 1.06

Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. J Clin Invest (2012) 1.06

Fine-mapping alleles for body weight in LG/J × SM/J F₂ and F(34) advanced intercross lines. Mamm Genome (2011) 1.05

Cue-reactors: individual differences in cue-induced craving after food or smoking abstinence. PLoS One (2010) 1.05

Distinct genetic regions modify specific muscle groups in muscular dystrophy. Physiol Genomics (2010) 1.05

Effectiveness of a marijuana expectancy manipulation: Piloting the balanced-placebo design for marijuana. Exp Clin Psychopharmacol (2009) 1.05

Diazepam impairs behavioral inhibition but not delay discounting or risk taking in healthy adults. Exp Clin Psychopharmacol (2006) 1.05

Differential effects of ethanol on serum GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in mice, rats, cynomolgus monkeys, and humans. Alcohol Clin Exp Res (2009) 1.04

Endocannabinoid signalling: has it got rhythm? Br J Pharmacol (2010) 1.04

Norepinephrine transporter gene variation modulates acute response to D-amphetamine. Biol Psychiatry (2007) 1.04

Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants. Am J Med Genet B Neuropsychiatr Genet (2005) 1.04

Attenuated cortisol response to alcohol in heavy social drinkers. Int J Psychophysiol (2005) 1.04

Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend (2013) 1.03

The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend (2002) 1.03

Contextual conditioning enhances the psychostimulant and incentive properties of d-amphetamine in humans. Addict Biol (2011) 1.02

Mecamylamine and ethanol preference in healthy volunteers. Alcohol Clin Exp Res (2005) 1.01

Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology (2012) 1.00

In the company of others: social factors alter acute alcohol effects. Psychopharmacology (Berl) (2013) 1.00

Personality and gender differences in effects of d-amphetamine on risk taking. Exp Clin Psychopharmacol (2007) 1.00

Delay of gratification and delay discounting in rats. Behav Processes (2002) 0.99

Amphetamine as a social drug: effects of d-amphetamine on social processing and behavior. Psychopharmacology (Berl) (2012) 0.99

A simulation study of permutation, bootstrap, and gene dropping for assessing statistical significance in the case of unequal relatedness. Genetics (2012) 0.98

Lack of association between COMT and working memory in a population-based cohort of healthy young adults. Neuropsychopharmacology (2013) 0.98

Quantifying reinforcement value and demand for psychoactive substances in humans. Curr Drug Abuse Rev (2012) 0.98

Challenges for translational psychopharmacology research--some basic principles. Psychopharmacology (Berl) (2008) 0.97

Rapid selection response for contextual fear conditioning in a cross between C57BL/6J and A/J: behavioral, QTL and gene expression analysis. Behav Genet (2008) 0.97

Therapeutic doses of diazepam do not alter impulsive behavior in humans. Pharmacol Biochem Behav (2004) 0.97

Genetic architecture of fear conditioning in chromosome substitution strains: relationship to measures of innate (unlearned) anxiety-like behavior. Mamm Genome (2007) 0.97

Effects of amphetamine on reactivity to emotional stimuli. Psychopharmacology (Berl) (2011) 0.97

Enhanced mood and psychomotor performance by a caffeine-containing energy capsule in fatigued individuals. Exp Clin Psychopharmacol (2008) 0.96

Csnk1e is a genetic regulator of sensitivity to psychostimulants and opioids. Neuropsychopharmacology (2011) 0.96

Differences in aggressive behavior and DNA copy number variants between BALB/cJ and BALB/cByJ substrains. Behav Genet (2009) 0.96

Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights. Front Genet (2012) 0.95

An association study of the brain-derived neurotrophic factor Val66Met polymorphism and amphetamine response. Am J Med Genet B Neuropsychiatr Genet (2006) 0.95

Stress-induced changes in mood and cortisol release predict mood effects of amphetamine. Drug Alcohol Depend (2010) 0.95

Serotonin transporter genotype and acute subjective response to amphetamine. Am J Addict (2006) 0.94

QTL Analysis of Type I and Type IIA Fibers in Soleus Muscle in a Cross between LG/J and SM/J Mouse Strains. Front Genet (2012) 0.93

Pavlovian fear memory circuits and phenotype models of PTSD. Neuropharmacology (2011) 0.93

The prescription opioid, oxycodone, does not alter behavioral measures of impulsivity in healthy volunteers. Pharmacol Biochem Behav (2009) 0.93